Results From Argos Therapeutics' Arcelis Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium

 

 

 

DURHAM, N.C., Sept. 24 /PRNewswire/ -- Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC.  Post-nephrectomy, subjects received sunitinib and then concomitant AGS-003.  The first endpoint was to evaluate clinical activity as measured by objective tumor response, and the secondary endpoints included safety, clinical activity via estimates of progression free survival, overall survival and assessment of clinical benefit as measured by stable disease, partial response, and CR rates and measurement of immune response.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases.  This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response.  To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease.  Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection.  The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:

 

 
 

David Schull or Andreas Marathovouniotis

 

Russo Partners LLC

 

(212) 845-4271 or (212) 845-4235

 

david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.com

 

 
 

Jeff Abbey

 

Argos Therapeutics

 

(919) 287-6308

 

jabbey@argostherapeutics.com

 
 


 

SOURCE Argos Therapeutics

CONTACT: David Schull, +1-212-845-4271, david.schull@russopartnersllc.com, or Andreas Marathovouniotis, +1-212-845-4235, andreas.marathis@russopartnersllc.com, both of Russo Partners LLC, or Jeff Abbey, Argos Therapeutics, +1-919-287-6308, jabbey@argostherapeutics.com
 

Web Site: http://www.argostherapeutics.com
 

Posted: September 2010

View comments

Hide
(web5)